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Abstract  25 
Salmonella Typhi is a human restricted Gram-negative bacterial pathogen, responsible for 26 
causing an estimated 27 million cases of typhoid fever annually leading to 217,000 deaths, 27 
and current vaccines do not offer full protection.  The O-antigen side chain of the 28 
lipopolysaccharide is an immunodominant antigen, can define host-pathogen interactions, 29 
and is under consideration as a vaccine target for some Gram-negative species. The 30 
composition of the O-antigen can be modified by activity of glycosyltransferase (gtr) operons 31 
acquired by horizontal gene transfer. Here we investigate the role of two gtr operons we 32 
identified in the S. Typhi genome.  Strains were engineered to express specific gtr operons. 33 
Full chemical analysis of the O-antigen of these strains identified gtr-dependent glucosylation 34 
and acetylation.  The glucosylated form of the O-antigen mediated enhanced survival in 35 
human serum and decreased complement binding. A single nucleotide deviation from an 36 
epigenetic phase variation signature sequence rendered expression of this glucosylating gtr 37 
operon uniform in the population.  In contrast, expression of the acetylating gtrC is controlled 38 
by epigenetic phase variation.  Acetylation did not affect serum survival, but phase variation 39 
can be an immune evasion mechanism and thus this modification may contribute to 40 
persistence in a host.  In murine immunization studies, both O-antigen modifications were 41 
generally immunodominant.  Our results emphasize that natural O-antigen modification 42 
should be taken into consideration when assessing responses to vaccines, especially O-43 
antigen based vaccines, and that the Salmonella gtr repertoire may confound the protective 44 
efficacy of broad ranging Salmonella lipopolysaccharide conjugate vaccines.  45 
 46 
 47 
48 
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INTRODUCTION 49 
Salmonella enterica subspecies enterica serovar Typhi  (S. Typhi) is responsible for an 50 
estimated 27 million new cases of typhoid fever and 217,000 deaths annually (1). Infection 51 
with S. Typhi occurs via the fecal-oral route; after ingestion, bacteria cross the intestinal 52 
epithelium, enter the bloodstream and spread systemically (2). In some cases, S. Typhi is 53 
capable of colonizing the gall bladder, leading to chronic asymptomatic shedding and 54 
contributing to the infection cycle. Two vaccines are currently licensed for use against S. 55 
Typhi: the parenterally administered Vi capsular polysaccharide subunit vaccine and the 56 
orally administered live-attenuated Ty21a vaccine. Neither vaccine offers complete 57 
protection (3) and there is on-going research into new vaccine formulations against S. Typhi 58 
and other Salmonella infections (3, 4).  Conjugate vaccines, combining carrier proteins with 59 
the Vi polysaccharide antigen are under development. However, Vi expression can be up- or 60 
down-regulated and Vi-negative isolates have been isolated from typhoid patients (5, 6).  61 
Lipopolysaccharide (LPS) is a Gram-negative bacterial virulence factor, a component of the 62 
outer membrane and, in the absence of Vi, is the predominant S. Typhi surface carbohydrate.  63 
Notably, the efficacy of the S. Typhi Ty21 vaccine is associated in part to expression of LPS 64 
(7).    65 
 66 
LPS is composed of a lipid A tail, which anchors the LPS into the membrane, a core 67 
oligosaccharide and O-antigen side chain. The surface-exposed O-antigen side chain protects 68 
the bacterial cell from the actions of the innate immune system (8).  The O-antigen is 69 
immunogenic, and may be a functional target for novel vaccines (9, 10).  The S. enterica 70 
subspecies is comprised of over 2,600 serovars, which is based on differences in the antigenic 71 
properties of the O and H (flagellar) antigens, and forms the basis of the Kauffman-White 72 
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serotyping system (11). Antibodies are raised during natural infection against the LPS and the 73 
detection of S. Typhi O-antigen antibodies forms the basis of the diagnostic Widal test for 74 
typhoid (12).  Furthermore, significant cross-reactivity between serovars sharing certain O-75 
antigen epitopes exists, which may be exploited in developing pan-Salmonella vaccines (13).  76 
Therefore, gaining insight into occurrence and significance of variation in S. Typhi O-antigen 77 
composition may enhance understanding of S. Typhi pathogenesis, and support the 78 
development of diagnostic and intervention tools and therapies.   79 
 80 
Modifications in LPS, including those in the O-antigen, play a role in many chronic bacterial 81 
infections (14).  O-antigen structures can be modified through several processes, and recently 82 
we identified and characterised numerous Salmonella gtr (glycosyltransferase) operons (15). 83 
Using the amino acid sequence identity of the GtrC O-antigen modifying proteins we were 84 
able to group the gtr operons into ten different “families” and proposed that each family 85 
performs a different O-antigen modification (15). We additionally noted that a single 86 
Salmonella isolate may harbour multiple gtr operons and several families of these gtr operons 87 
can undergo phase variation (15, 16), thus generating further potential complexity of the O-88 
antigen presented by a population.  If, as a result, clonal bacterial populations have a non-89 
uniform O-antigen composition, this could serve as a means of immune evasion (17-19).  90 
 91 
The significance of gtr-mediated O-antigen modification for Salmonella biology is not fully 92 
understood.  In S. Typhimurium specific modifications have been implicated in gut 93 
colonization (20) and in phage resistance (21).  To better understand the extent and impact of 94 
O-antigen variation, we aimed to characterize the activity and expression of the gtr repertoire 95 
in S. Typhi.  Given that S. Typhi causes a systemic infection and that evading the innate 96 
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immune response can contribute to persistence, we measured the effect of gtr modification on 97 
serum sensitivity. Further, we assessed the antibody response towards each O-antigen 98 
modification in serum from a murine immunization model. 99 
 100 
MATERIALS AND METHODS 101 
Bacterial strains and culture conditions 102 
Strains were grown in LB unless mentioned otherwise.  For S. Typhi BRD948, medium was 103 
supplemented with an Aro mix (final concentrations: 40 µM L-phenylalanine, 40 µM L-104 
tryptophan, 1 µM para-aminobenzoic acid, and 1 µM 2,3-dihydroxybenzoic acid, tyrosine 40 105 
µM). Antibiotic were used at the following concentrations: tetracycline (15 µg/ml), 106 
ampicillin (100 µg/ml), chloramphenicol (34 µg/ml for vectors or 8 µg/ml for chromosomal 107 
inserts) or kanamycin (30 µg/ml).  S Typhi BRD948 and its derivatives were confirmed to be 108 
Vi+ by serum agglutination (Vi antiserum, Serum Statens Institute).  For analysis of LacZ 109 
expression, strains were grown on minimal M9 media (Sigma, Gilingham, UK) with 0.2% 110 
glucose (S. Typhimurium) or LB ( S. Typhi) with 40 µg/ml X-gal (5-Bromo-4-chloro-3-111 
indolyl-ß-D-galactoside, Melford). Strains are listed in Supplemental Table S1.  112 
 113 
Molecular biology, strain construction and mutagenesis 114 
Standard molecular biology techniques were used (22). Details on vectors and primers used 115 
in these studies are provided in Supplemental Table S1.  Strains containing a lacZ reporter 116 
fusion on the chromosome at the attB site were generated using the CRIM system (23) using 117 
vector pMV243 (24).  Allelic replacement was used to introduce mutations to the 118 
chromosome (25). Antibiotic resistance cassettes were obtained from Tn10 for TcR and 119 
pKD4 for KmR (25).  Unmarked strains were generated by removal of the pKD13 derived 120 
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KmR cassette by Flp recombinase expressed from pCP20 (26). Vectors, and primer details 121 
are provided in Table S1. 122 
 123 
Analysis of gene expression. 124 
β-galactosidase assays on strains with lacZ reporter fusions were performed as described by 125 
Miller (27). Cultures derived from two independent colonies were grown in M9 minimal 126 
media with glucose. Samples were collected at least in triplicate between OD600 0.3-1.5 for 127 
measurement of β-galactosidase activity, given in Miller Units.  The switch frequency of 128 
phase variation was calculated for two independent colonies each for a Lac+ or Lac- 129 
phenotype as described (28). The switch frequency is expressed as number of cells that have 130 
changed expression state (M) over total number of cells (N), divided by the number of 131 
generations (g). 132 
 133 
LPS extraction and visualization 134 
Crude LPS extracts were prepared as described (15), separated on a Tricine SDS-PAGE and 135 
O-antigen visualized using a silver stain (15) or Western blot. These crude extracts can 136 
incidentally contain contaminating macromolecules that are apparent on the gels or Westerns.  137 
For Western blots, the samples were transferred to PVDF and blocked with 5% milk PBS-T. 138 
O12, OMA polyvalent antiserum mixture to salmonella O-antigen from Group A, B, D, E, L  139 
(Serum Statens Institute) or O122 sera were used to probe blots as indicated using secondary 140 
goat anti rabbit IgG-HRP [Sigma (A0545)]. When mouse serum was used, goat anti-mouse 141 
IgG-HRP (A1068) served as secondary. Millipore’s Luminato Western HRP substrate was 142 
used for detection.  143 
 144 
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Serum sensitivity assay 145 
Human serum was purchased from Sigma (H4522). This serum failed to agglutinate the S. 146 
Typhi strains. S. Typhi strains were grown over night and then diluted to an OD600 = 0.5 in 147 
PBS. 5ul of bacteria were added to 45ul of serum diluted in PBS and incubated one hour at 148 
37˚C. Dilutions were performed to determine colony-forming units. Survival was determined 149 
by comparing counts to those obtained from a control that was incubated in 45ul PBS. 150 
Experiments were performed in duplicate and repeated at least three times. 151 
 152 
C3 binding to bacterial surface 153 
Experiments were performed using stationary phase bacteria. Methods were adapted from 154 
MacClennan et al. (29), following quantities similar to the serum sensitivity experiments. 155 
Briefly, bacteria were incubated with full strength human serum followed by incubation with 156 
Dako’s polyclonal rabbit anti-human C3c complement FITC antibody (F-0201). A Beckman 157 
Coulter CyAn ADP analyser was used to collect data. Bangs FITC-5 MESF kit (Cat# 555) 158 
allowed for standardization of fluorescence across experiments.  159 
 160 
Generation of murine immune serum  161 
Female Slc11a1D169 (Nramp1s ) C57BL/6 CD45.1 mice were obtained from Charles River 162 
UK, housed under specific pathogen-free conditions and used at 6–10 weeks of age. All 163 
experiments were approved by the University of York Animal Welfare and Ethical Review 164 
Body and performed under UK home Office license. For immunizations, bacteria from 165 
overnight cultures was diluted to an OD600 = 1.0 in PBS. 200ul was given IP, resulting in an 166 
inoculum ranging from 8.12 x 107 to 2.56 x 108 CFU. 28 days after immunization mice were 167 
exsanguinated by cardiac puncture under terminal anaesthesia. Serum was obtained by 168 
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allowing the collected blood to coagulate overnight at 4°C, then centrifuging at 2000rpm for 169 
2 minutes. The serum layer could then be removed and stored at   -20°C until use. Nine mice 170 
were immunised with the STy-basal strain and seven immunised with the STy- FM strain. 171 
 172 
RESULTS 173 
The genomes of the S. Typhi strains Ty2, CT18 and P-stx-12 (isolated from a chronic carrier 174 
in India) (30) each contain two different gtr operons (15). These share sequence identity 175 
between the S. Typhi strains.  One operon is a family 3 gtr type with high identity (99% 176 
amino acid) to the S. Typhimurium family 3 operon (STM0557-0559) that mediates α1->4 177 
glucosylation of the O-antigen galactose sugar (20). The second gtr operon could be grouped 178 
with the family 2 GtrCs and shared 77% amino acid identity with a similar operon in the 179 
invasive S. Typhimurium isolate D23580. This GtrC operon has been hypothesised to 180 
acetylate the rhamnose residue of the O-antigen (21); the S. Typhi O-antigen has a rhamnose 181 
residue, but no acetylation has been described.  182 
 183 
To assess the role of the S. Typhi gtr operons, we generated a set of four otherwise isogenic S. 184 
Typhi strains with a defined gtr expression pattern: STy-Basal (both gtr operons deleted); 185 
STy-Acetyl (expressing only family 2); STy-Gluc (expressing only family 3); and STy-FM 186 
(both gtr operons expressed). LPS from these isogenic strains was extracted and compared by 187 
Western blotting (Fig 1; Fig S1). The O-antigen of all strains reacted with commercial 188 
Salmonella serum, confirming all strains expressed O-antigen (Fig. 1A) and that production 189 
of the long antigen structure was not affected. Factor O122 serum targets the α1-4 190 
glucosylation of the galactose (31), and the O-antigens of the parent S. Typhi strain, STy-191 
Gluc and STy-FM reacted with this serum; strains lacking expression of family 3 gtr did not 192 
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react with this serum (Fig. 1A). Silver staining showed that strains expressing family 3 gtr 193 
had a distinct O-antigen laddering pattern compared to isolates that lacked family 3 gtr (Fig. 194 
S1). These data indicate the family 3 gtr operon of S. Typhi performs the same O-antigen 195 
modification as the family 3 gtr operon of S. Typhimurium, namely α1-4 glucosylation of 196 
the galactose. However, no visible shift in the O-antigen pattern for STy-Acetyl compared to 197 
STy-Basal was observed, providing further evidence the family 2 GtrC does not act as a 198 
glucosyltransferase. 199 
 200 
Chemical analysis of the O-antigen from S. Typhi strains 201 
To define the composition and linkages of the gtr-dependent modifications various chemical 202 
analyses were performed on LPS isolated from the S. Typhi parent strain and isogenic 203 
variants. Full details are available with Supplemental Figures S2 and S3, and Tables S2-S4. A 204 
methylation analysis of the LPS of these strains showed only minor differences in the 205 
proportion of the linkages present in the polysaccharide (Table 1). The S. Typhi parent strain 206 
and both STy-Gluc, STy-FM showed glucosylation on O-4 of galactose, at 62.3%, 82.4% and 207 
82.5%, respectively, deduced from the galactose linkages. Nuclear magnetic resonance 208 
(NMR) analysis revealed that the extent of glucosylation was comparable to that derived 209 
from the methylation analysis (Table S2, Fig. S2) [parent (55.9%), STy-Gluc (72.8%) and 210 
STy-FM (71.2%)].   211 
 212 
In contrast to the methylation analysis, in which O-acetyl groups are removed during the acid 213 
hydrolysis, NMR on untreated LPS (no lipid A removal) permits identification of acetylation. 214 
We recorded an O-acetylation signal from both parent S. Typhi and STy-FM untreated LPS 215 
(both encode family 2gtr) (Fig. S2), but this signal was absent in the spectra from STy-Gluc. 216 
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A further evaluation identified a 4-linked 3-O-acetyl rhamnose and a 4-linked 2-O-acetyl-217 
rhamnose (Fig. S3, Table S4). The two states likely reflect a single modification event, with 218 
subsequent migration of the acetyl group (32).  The parent S. Typhi strain exhibited the same 219 
pattern of peaks in all NMR spectra as the STy-FM strain, with only slight disparities in 220 
intensity of the acetylated positions (50% and 67%, respectively), with O-2 and O-3 of 221 
rhamnose in approximately equal abundance. Taken together we confirm that the S. Typhi 222 
family 3 gtr operon mediates α1>4 glucosylation of the galactose and show that the family 2 223 
gtr operon acts as a rhamnose acetyltransferase (Fig. 1C.)  224 
 225 
The expression patterns of the two S. Typhi gtr operons differ  226 
The expression of multiple gtr operons in S. enterica is controlled by phase variation (16). 227 
This regulation is associated with a signature sequence in the regulatory region of gtrA 228 
comprised of two binding sites for the transcriptional regulatory protein OxyR and four 229 
GATC sites. The GATC sites are the target sequence for Dam, a “maintenance” adenine 230 
DNA methyltransferase. DNA methylation-dependent interaction of OxyR at the gtr binding 231 
sites leads to epigenetic phase variation of gtr expression (15, 16).  In S. Typhi, this signature 232 
sequence is present in the regulatory region of the family 2 gtr regulatory region and, 233 
therefore, we predicted this operon to undergo phase variation. In contrast, the family 3 234 
operon has the OxyR binding sequences but only three GATC sequences, with GAAA at the 235 
fourth, promoter proximal, GATC sequence (Fig. 2).    236 
  237 
The expression of both gtr operons was assessed using single copy transcriptional lacZ 238 
fusions. In S. Typhimurium and S. Typhi backgrounds, family 2 expression was controlled by 239 
phase variation. The switch frequency of the ON phase to the OFF phase was similar to that 240 
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for the reverse switch (Table 2). Therefore, in the absence of selective pressure, a clonal 241 
population should consist of similar numbers of cells with and without the family 2-mediated 242 
modification. In contrast, the strain with the lacZ reporter for the family 3 gtr operon gave 243 
rise to only Lac+ colonies, indicating the S. Typhi family 3 gtr operon is expressed but not 244 
controlled by phase variation.  Mutating GAAA back to GATC restored phase variation to 245 
this family 3gtr operon (data not shown).  These data indicate that a clonal S. Typhi 246 
population is likely to have a uniform O-antigen glycosylation pattern, but heterogeneous at 247 
the single cell level with respect to O-antigen acetylation. 248 
 249 
Effect of gtr modifications on serum sensitivity 250 
S. Typhi spreads systemically during typhoid fever; therefore the infecting organisms must 251 
have reliable mechanisms for survival in the presence of components of the innate immune 252 
system. The O-antigen can contribute to serum survival. We next assessed whether gtr 253 
expression and its effects on O-antigen composition affects serum resistance in S. Typhi.    254 
 255 
Serum sensitivity of the various isogenic S. Typhi was measured using a commercially 256 
available human serum (Fig. 3A). The two strains containing the family 3-mediated 257 
glucosylation had greater resistance to serum killing than the STy-Basal or STy-Acetyl 258 
strains that both lack glucosylation. Acetylation of the O-antigen did not afford any 259 
significant survival benefit compared to STy-basal in any of the conditions tested. Taken 260 
together, these results imply that complement-mediated killing of S. Typhi is altered by the 261 
gtr-dependent glucosylation of the O-antigen. 262 
 263 
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To corroborate differences in serum sensitivity between glucosylated and non-glucosylated 264 
strains, we next assessed C3 complement protein binding to the strains. C3 initiates alternate 265 
pathway activation, leading to the formation of membrane attack complex (MAC). After 266 
incubation in naïve human serum, cells were exposed to FITC conjugated anti-C3 antibody 267 
and surface-bound C3 measured with flow cytometry. Non-glucosylated strains (STy-Basal 268 
and STy-Acetyl) exhibited significantly more surface-bound fluorescence than glucosylated 269 
strains (STy-Gluc and STy-FM) (Fig. 3B). Acetyl modification did not significantly alter C3-270 
binding (comparison between STy-Basal to STy-Acetyl and STy-Gluc to STy-FM).  271 
 272 
Recognition of S. Typhi O-antigen from a murine immunization model 273 
We assessed whether O-antigen modification affected the specificity of antibodies generated 274 
in a murine immunization model.  Mice were immunized with either STy-Basal (no O-275 
antigen modification) or STy-FM (acetylated and glycosylated O-antigen) and serum was 276 
collected. LPS from the four strains with defined gtr expression was used in a Western blot 277 
assay and probed with serum from individual mice (Fig. 4).  This approach allowed 278 
identification of the O-antigen moieties recognized by antibody, and discrimination from 279 
antibody directed to the shared lipid A and core. 280 
 281 
Irrespective of the immunizing strain, there was variation between the responses of individual 282 
mice (Fig. 4A & B).  Immunization with non-modified O-antigen uniformly resulted in 283 
recognition of lipid A + core (Fig. 4A). Some animals (3/9, i.e. panel 10) failed to show any 284 
additional recognition of the O-antigen structures.  When an O-antigen response was evident, 285 
the composition of O-antigen from the immunizing strain was most frequently recognized 286 
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 13
(5/9), and in some cases the only O-antigen that was recognized (3/9; i.e. panel 3) Notably, 287 
only one serum recognized all four forms of S. Typhi O-antigen (e.g. panel 2).   288 
 289 
In contrast, in mice immunized with the STy-FM strain expressing a fully modified O-290 
antigen, the unmodified form of O-antigen was only recognized in 1/7 mice (e.g. panel 7), 291 
suggesting a general immunodominance of the gtr-dependent modifications (Fig. 4B).  292 
In only 3/7, e.g. panel 4, all three modified O-antigen forms were recognized.  The remaining 293 
mice produced antibodies specific for either the glucosylated or the acetylated form despite 294 
having been immunized with a strain expressing both modifications.  These data predict that 295 
gtr-mediated modifications mostly are immunodominant over the unmodified form (Sty-296 
Basal), but that neither acylation nor glucosylation is preferentially recognized after 297 
immunization with a strain expressing O-antigen with both modifications. 298 
 299 
DISCUSSION 300 
The occurrence of strain and serovar-dependent O-antigen modification in the Salmonellae 301 
has long been recognized (33), but only recently has the potential for gtr-mediated 302 
modification been described in this genus (15). Here, we investigated two gtr operons in the 303 
human host-restricted pathogen S. Typhi. Our data show that the family 3 gtr operon 304 
catalyses a α1->4 glucosylation of the galactose, as has been previously described for a 305 
family 3 gtr operon for the serovar S. Typhimurium (20). Additionally, we demonstrate that 306 
the family 2 gtr is required for acetylation of the rhamnose, as was suggested previously (21).  307 
Thus, family 2 GtrC is not a glycosyltransferase but an acyltransferase, and the gtr acryonym 308 
thus only reflects proximity to (remnant) gtrAB genes (15).  The galactose glucosylation in 309 
the S. Typhi O-antigen was previously reported (33), but this is, to our knowledge, the first 310 
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report of rhamnose acetylation in S. Typhi. Acetylation of the family 3-dependent glucose 311 
modification also may occur but the genes encoding this process remain to be identified (33, 312 
34).  313 
 314 
Acetylation of the rhamnose moiety will be heterogeneous in a bacterial population due to 315 
phase variation of expression of family 2 gtr.  This is consistent with a role in, and a 316 
mechanism of, immune evasion (19). In contrast, the STy family 3 gtr regulatory region 317 
deviates from the known phase variation signature sequence in one GATC sequence, which 318 
caused abrogation of phase variation. Thus, glucosylation should be uniformly expressed 319 
among cells in a population, likely contributing to the high degree of glucosylation observed 320 
in S. Typhi O-antigen compared with other Salmonella serovars (34, 35).  The sequence 321 
variation associated with this lack of phase variation is present in both CT18 and Ty2 S. 322 
Typhi genomes.   323 
 324 
O-antigen glucosylation has implications for virulence in non-typhoidal serovars. In S. 325 
Typhimurium, family 3-dependent glucosylation is associated with increased persistence in 326 
the mouse intestine (20), and glucosylation of the S. Enteritidis O-antigen is associated with 327 
an increase in virulence in a chicken-to-egg transmission model (35). The role we identified 328 
for family 3-dependent glucosylation in serum resistance adds to the evidence that O-antigen 329 
glucosylation can affect Salmonella–host interactions (14, 36).  This one finding does not 330 
exclude further benefits of this modification for S. Typhi. 331 
 332 
Antibody recognition of a pathogen is an important feature for the clearance of infection.  In 333 
S. Typhi, the Vi capsular polysaccharide contributes to immune evasion (37) and antigen O9 334 
 o
n
 February 28, 2017 by University of East Anglia
http://iai.asm
.org/
D
ow
nloaded from
 
 15
antibodies can affect antibody mediated serum resistance.  This role of O9 antibodies may be 335 
relevant for antibody-mediated killing when there is reduced Vi capsule expression during 336 
the infection cycle (38, 39).  Our data highlight that both gtr mediated O-antigen 337 
modifications can influence antibody recognition of the O-antigen.  The trend from the 338 
murine model was that immunization with a strain with modified O-antigen generated 339 
antibodies that predominantly recognized the modified version of Salmonella O-antigen and 340 
did not recognize the basal, unmodified O-antigen.  These modifications thus could impact on 341 
antibody-dependent killing mechanisms during S. Typhi infection. 342 
 343 
In other Salmonella serovars, dominant epitopes induced by O-antigen modification have 344 
been shown to be relevant for eliciting a protective immune response.  For example, OafA-345 
dependent acetyl-modification of the abequose is required for protective antibodies against S. 346 
Typhimurium (40, 41).  A protective S. Paratyphi A glycoconjugate LPS vaccine required 347 
acetylation, which is likely dependant on the described rhamnose acetylation modification 348 
(42, 43).  Based on the data presented here linking rhamnose acetylation to family 2 gtr, this 349 
can now be attributed to the family 2 gtr encoded in the S. Paratyphi A genome (15).  350 
Rhamnose acetylation was also implicated in the strain-specific dominant epitope of the 351 
invasive S. Typhimurium D23580 isolate (41), which also can be attributed to the phage 352 
encoded family 2 gtr that is expressed in this specific strain (21).   However, detailed 353 
analyses in context of the host, disease and serovars are needed to further clarify the impact 354 
of O-antigen acetylation and glucosylation (44) (45).   355 
 356 
Our results expand the body of evidence demonstrating that O-antigen composition in 357 
Salmonella impacts upon host-pathogen interactions during infection. Strains within a 358 
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specific serovar may have a different repertoire of O-antigen modifying genes, and 359 
expression may fluctuate by phase variation. Consequently, antibody generated by primary 360 
infection or immunization may not wholly recognize subsequent infections by the same 361 
serovar.   Indeed, disease associated S. Typhi strains are not clonal and the genetic repertoire 362 
of O-antigen modifying genes may vary (15, 46, 47).    Furthermore, the response to the 363 
Ty21a oral vaccine elicits a strong O-antigen antibody response, and thus any factors that 364 
modify this response may impact serovar and strain cross-reactivity.  In conclusion, we 365 
suggest that O-antigen modification repertoires may need to be considered in vaccine design 366 
to enhance efficacy against a broad range of S. Typhi isolates and phenotypes. 367 
  368 
 369 
Acknowledgements 370 
We thank Peter Roggentin for providing the O122 serum, Rob Kingsley for the BRD948 S. 371 
Typhi strain, and Jane Dalton for assistance with the murine immunization experiments. 372 
 373 
Funding Statement 374 
This work was supported by the Wellcome Trust of the United Kingdom, through the project 375 
grant WT094333MA awarded to MvdW. SB is a Sir Henry Dale Fellow, jointly funded by 376 
the Wellcome Trust and the Royal Society (100087/Z/12/Z).  Work carried out at the CCRC 377 
was supported by U.S. Department of Energy grant (DE-SC0015662) to PA.  The funders had 378 
no role in study design, data collection and interpretation. 379 
 380 
 381 
 382 
 o
n
 February 28, 2017 by University of East Anglia
http://iai.asm
.org/
D
ow
nloaded from
 
 17
References 383 
1. Crump JA, Luby SP, Mintz ED. 2004. The global burden of typhoid fever. Bull World 384 
Health Organ 82:346-53. 385 
2. Snyder MJ, Hornick RB, McCrumb FR, Jr., Morse LJ, Woodward TE. 1963. Asymptomatic 386 
Typhoidal Bacteremia in Volunteers. Antimicrob Agents Chemother (Bethesda) 387 
161:604-7. 388 
3. Martin LB. 2012. Vaccines for typhoid fever and other salmonelloses. Curr Opin Infect 389 
Dis 25:489-99. 390 
4. MacLennan CA, Martin LB, Micoli F. 2014. Vaccines against invasive Salmonella disease: 391 
current status and future directions. Hum Vaccin Immunother 10:1478-93. 392 
5. Baker S, Sarwar Y, Aziz H, Haque A, Ali A, Dougan G, Wain J. 2005. Detection of Vi-393 
negative Salmonella enterica serovar typhi in the peripheral blood of patients with 394 
typhoid fever in the Faisalabad region of Pakistan. J Clin Microbiol 43:4418-25. 395 
6. Janis C, Grant AJ, McKinley TJ, Morgan FJ, John VF, Houghton J, Kingsley RA, Dougan G, 396 
Mastroeni P. 2011. In vivo regulation of the Vi antigen in Salmonella and induction of 397 
immune responses with an in vivo-inducible promoter. Infect Immun 79:2481-8. 398 
7. Germanier R, Fuer E. 1975. Isolation and characterization of Gal E mutant Ty 21a of 399 
Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis 131:553-400 
8. 401 
8. Murray GL, Attridge SR, Morona R. 2006. Altering the length of the lipopolysaccharide O 402 
antigen has an impact on the interaction of Salmonella enterica serovar Typhimurium 403 
with macrophages and complement. J Bacteriol 188:2735-9. 404 
9. MacLennan CA. 2014. Antibodies and protection against invasive salmonella disease. 405 
Front Immunol 5:635. 406 
 o
n
 February 28, 2017 by University of East Anglia
http://iai.asm
.org/
D
ow
nloaded from
 
 18
10. Nagy G, Pal T. 2008. Lipopolysaccharide: a tool and target in enterobacterial vaccine 407 
development. Biol Chem 389:513-20. 408 
11. Grimont PAD, Weill F-X. 2007.  Antigenic formulae of the Salmonella serovars. 409 
9th edition, on WHO Collaborating Centre for Reference and Research on 410 
Salmonella, Institut Pasteur, Paris. Accessed  411 
12. House D, Wain J, Ho VA, Diep TS, Chinh NT, Bay PV, Vinh H, Duc M, Parry CM, Dougan G, 412 
White NJ, Hien TT, Farrar JJ. 2001. Serology of typhoid fever in an area of endemicity and 413 
its relevance to diagnosis. J Clin Microbiol 39:1002-7. 414 
13. Kantele A, Pakkanen SH, Siitonen A, Karttunen R, Kantele JM. 2012. Live oral typhoid 415 
vaccine Salmonella Typhi Ty21a - a surrogate vaccine against non-typhoid salmonella? 416 
Vaccine 30:7238-45. 417 
14. Maldonado RF, Sa-Correia I, Valvano MA. 2016. Lipopolysaccharide modification in 418 
Gram-negative bacteria during chronic infection. FEMS Microbiol Rev 40:480-93. 419 
15. Davies MR, Broadbent SE, Harris SR, Thomson NR, van der Woude MW. 2013. 420 
Horizontally acquired glycosyltransferase operons drive salmonellae lipopolysaccharide 421 
diversity. PLoS Genet 9:e1003568. 422 
16. Broadbent SE, Davies MR, van der Woude MW. 2010. Phase variation controls 423 
expression of Salmonella lipopolysaccharide modification genes by a DNA methylation-424 
dependent mechanism. Mol Microbiol. 425 
17. Hone DM, Harris AM, Chatfield S, Dougan G, Levine MM. 1991. Construction of 426 
genetically defined double aro mutants of Salmonella typhi. Vaccine 9:810-6. 427 
18. van der Woude MW. 2006. Re-examining the role and random nature of phase variation. 428 
FEMS Microbiol Lett 254:190-7. 429 
19. van der Woude MW, Baumler AJ. 2004. Phase and antigenic variation in bacteria. Clinical 430 
Microbiology Reviews 17:581-+. 431 
 o
n
 February 28, 2017 by University of East Anglia
http://iai.asm
.org/
D
ow
nloaded from
 
 19
20. Bogomolnaya LM, Santiviago CA, Yang HJ, Baumler AJ, Andrews-Polymenis HL. 2008. 432 
'Form variation' of the O12 antigen is critical for persistence of Salmonella 433 
Typhimurium in the murine intestine. Mol Microbiol 70:1105-19. 434 
21. Kintz E, Davies M, Hammarlof DL, Canals R, Hinton JC, van der Woude M. 2015. A BTP1 435 
prophage gene present in invasive non-typhoidal Salmonella determines composition 436 
and length of the O-antigen of the LPS. Mol Microbiol doi:10.1111/mmi.12933. 437 
22. Sambrook J, Fritsch E, Maniatis T. 1987. Molecular Cloning: A Laboratory Manual. 438 
Cold Spring Harbor Laboratory Press, Plain View. 439 
23. Haldimann A, Wanner BL. 2001. Conditional-replication, integration, excision, 440 
and retrieval plasmid-host systems for gene structure-function studies of 441 
bacteria. J Bacteriol 183:6384-93. 442 
24. Kaminska R, van der Woude MW. 2010. Establishing and maintaining sequestration of 443 
Dam target sites for phase variation of agn43 in Escherichia coli. J Bacteriol 192:1937-444 
45. 445 
25. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in 446 
Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97:6640-5. 447 
26. Cherepanov PP, Wackernagel W. 1995. Gene disruption in Escherichia coli: TcR 448 
and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-449 
resistance determinant. Gene 158:9-14. 450 
27. Miller J. 1972. Experiments in molecular genetics. Cold Spring Harbor Laboratory, 451 
Cold Spring Harbor, N. Y. 452 
28. Blyn LB, Braaten BA, White-Ziegler CA, Rolfson DH, Low DA. 1989. Phase-variation of 453 
pyelonephritis-associated pili in Escherichia coli: evidence for transcriptional regulation. 454 
EMBO J 8:613-20. 455 
 o
n
 February 28, 2017 by University of East Anglia
http://iai.asm
.org/
D
ow
nloaded from
 
 20
29. MacLennan CA, Gondwe EN, Msefula CL, Kingsley RA, Thomson NR, White SA, Goodall M, 456 
Pickard DJ, Graham SM, Dougan G, Hart CA, Molyneux ME, Drayson MT. 2008. The 457 
neglected role of antibody in protection against bacteremia caused by nontyphoidal 458 
strains of Salmonella in African children. J Clin Invest 118:1553-62. 459 
30. Ong SY, Pratap CB, Wan X, Hou S, Abdul Rahman AY, Saito JA, Nath G, Alam M. 2012. 460 
Complete genome sequence of Salmonella enterica subsp. enterica serovar Typhi P-stx-461 
12. J Bacteriol 194:2115-6. 462 
31. Makela PH. 1973. Glucosylation of lipopolysaccharide in Salmonella: mutants 463 
negative for O antigen factor 1221. J Bacteriol 116:847-56. 464 
32. Reicher F, Gorin PAJ, Sierakowski MR, Correa JBC. 1989. Highly Uneven Distribution of 465 
O-Acetyl Groups in the Acidic D-Xylan of Mimosa-Scabrella (Bracatinga). Carbohydrate 466 
Research 193:23-31. 467 
33. Reeves P. 1993. Evolution of Salmonella O antigen variation by interspecific gene 468 
transfer on a large scale. Trends Genet 9:17-22. 469 
34. Hellerqvist CG, Lindberg B, Svensson S, Holme T, Lindberg AA. 1969. Structural studies 470 
on the O-specific side chains of the cell wall lipopolysaccharides from Salmonella typhi 471 
and S. enteritidis. Acta Chem Scand 23:1588-96. 472 
35. Rahman MM, Guard-Petter J, Carlson RW. 1997. A virulent isolate of Salmonella 473 
enteritidis produces a Salmonella typhi-like lipopolysaccharide. J Bacteriol 474 
179:2126-31. 475 
36. Lerouge I, Vanderleyden J. 2002. O-antigen structural variation: mechanisms and 476 
possible roles in animal/plant-microbe interactions. FEMS Microbiol Rev 26:17-47. 477 
37. Crawford RW, Wangdi T, Spees AM, Xavier MN, Tsolis RM, Baumler AJ. 2013. Loss of 478 
very-long O-antigen chains optimizes capsule-mediated immune evasion by Salmonella 479 
enterica serovar Typhi. MBio 4. 480 
 o
n
 February 28, 2017 by University of East Anglia
http://iai.asm
.org/
D
ow
nloaded from
 
 21
38. Bravo D, Silva C, Carter JA, Hoare A, Alvarez SA, Blondel CJ, Zaldivar M, Valvano MA, 481 
Contreras I. 2008. Growth-phase regulation of lipopolysaccharide O-antigen chain 482 
length influences serum resistance in serovars of Salmonella. J Med Microbiol 57:938-46. 483 
39. Hart PJ, O'Shaughnessy CM, Siggins MK, Bobat S, Kingsley RA, Goulding DA, Crump JA, 484 
Reyburn H, Micoli F, Dougan G, Cunningham AF, MacLennan CA. 2016. Differential 485 
Killing of Salmonella enterica Serovar Typhi by Antibodies Targeting Vi and 486 
Lipopolysaccharide O:9 Antigen. PLoS One 11:e0145945. 487 
40. Slauch JM, Mahan MJ, Michetti P, Neutra MR, Mekalanos JJ. 1995. Acetylation (O-factor 5) 488 
affects the structural and immunological properties of Salmonella typhimurium 489 
lipopolysaccharide O antigen. Infect Immun 63:437-41. 490 
41. Lanzilao L, Stefanetti G, Saul A, MacLennan CA, Micoli F, Rondini S. 2015. Strain Selection 491 
for Generation of O-Antigen-Based Glycoconjugate Vaccines against Invasive 492 
Nontyphoidal Salmonella Disease. PLoS One 10:e0139847. 493 
42. Konadu E, Shiloach J, Bryla DA, Robbins JB, Szu SC. 1996. Synthesis, characterization, 494 
and immunological properties in mice of conjugates composed of detoxified 495 
lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on 496 
the role of O acetyls. Infect Immun 64:2709-15. 497 
43. Ravenscroft N, Cescutti P, Gavini M, Stefanetti G, MacLennan CA, Martin LB, Micoli F. 498 
2015. Structural analysis of the O-acetylated O-polysaccharide isolated from Salmonella 499 
paratyphi A and used for vaccine preparation. Carbohydr Res 404:108-16. 500 
44. Rondini S, Micoli F, Lanzilao L, Gavini M, Alfini R, Brandt C, Clare S, Mastroeni P, Saul A, 501 
MacLennan CA. 2015. Design of Glycoconjugate Vaccines against Invasive African 502 
Salmonella enterica Serovar Typhimurium. Infect Immun 83:996-1007. 503 
45. Onsare RS, Micoli F, Lanzilao L, Alfini R, Okoro CK, Muigai AW, Revathi G, Saul A, Kariuki 504 
S, MacLennan CA, Rondini S. 2015. Relationship between Antibody Susceptibility and 505 
 o
n
 February 28, 2017 by University of East Anglia
http://iai.asm
.org/
D
ow
nloaded from
 
 22
Lipopolysaccharide O-Antigen Characteristics of Invasive and Gastrointestinal 506 
Nontyphoidal Salmonellae Isolates from Kenya. Plos Neglected Tropical Diseases 9. 507 
46. Wong VK, Baker S, Connor TR, Pickard D, Page AJ, Dave J, Murphy N, Holliman R, Sefton 508 
A, Millar M, Dyson ZA, Dougan G, Holt KE. 2016. An extended genotyping framework for 509 
Salmonella enterica serovar Typhi, the cause of human typhoid. Nat Commun 7:1287. 510 
47. Roumagnac P, Weill FX, Dolecek C, Baker S, Brisse S, Chinh NT, Le TA, Acosta CJ, Farrar J, 511 
Dougan G, Achtman M. 2006. Evolutionary history of Salmonella typhi. Science 512 
314:1301-4. 513 
  514 
 o
n
 February 28, 2017 by University of East Anglia
http://iai.asm
.org/
D
ow
nloaded from
 
 23
Table 1. Methylation analysis of the three LPS samples. 515 
No. Glycosyl Linkage Mole per cent 
  BRD948 STy-Gluc STy-FM 
a t-Tyv 0.2 2.3 3.0 
b 4-Rha 13.2 15.4 17.2 
c t-Glc 17.6 15.2 19.4 
d 2-Man or 3-Man 1.8 3.0 3.2 
e 3-Gal 6.8 3.6 3.3 
f 4-Glc 24.7 20.4 19.7 
g 2,3-Man 15.6 16.2 15.9 
h 3,4-Gal 11.3 16.8 15.6 
i 4,6-Glc 1.5 1.6 0.8 
DGa 62.3 82.4 82.5 
aDG (degree of glucosylation)=(h/(h+e)*100) 516 
 517 
 518 
Table 2. Expression of S. Typhi gtr operons 519 
a. Standard deviations are shown in parenthesis. Miller units were calculated for 100% 520 
ON cells for phase varying isolates.  521 
 522 
Strain Lac phenotype Miller Unitsa  
ON to OFF 
switch frequency 
OFF to ON 
switch frequency 
LT2F2reg-lacZ Lac+/Lac- 1116 (42) 3.0 x 10-3 3.3 x 10-3 
LT2F3reg-lacZ Lac+ 763 (28) n/a n/a 
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Figure Legends  523 
Figure 1. Effect of gtr modifications on S. Typhi O-antigen. 524 
 (A) Expression of family 3 gtr leads to recognition by O122 sera. LPS was prepared as 525 
described in the methods and run on TSDS-PAGE. Blots were probed with commercial OMA 526 
sera (top panel) and O122 sera (bottom panel). B = STy-Basal; WT = parent strain BRD948 527 
(“wild-type”) S. Typhi; Ac = STy-acetyl; G = STy-gluc; FM = STy-FM. 528 
(B) Summary of results from the chemical analysis of S. Typhi BRD948 O-antigen.  529 
(C) Schematic of the O-antigen of engineered strains used in these studies. See Figure S1 for 530 
additional silver stain analysis of the S. Typhi O-antigen. 531 
 532 
 533 
Figure 2. Alignment of S. Typhi gtr regulatory regions to the phase varying regulatory 534 
region of the S. Typhimurium family 3 gtr operon.  535 
The GATC sites are underlined and the OxyR binding sites are outlined in light gray boxes. 536 
The -35/-10 sigma sites and the +1 transcriptional start site are indicated. Alignment was 537 
performed in TCOFFEE. 538 
 539 
Figure 3. Serum sensitivity of S. Typhi strains with different gtr modifications. 540 
 (A) Results from the serum survival assay for strains grown to stationary phase and 541 
incubated in 50% serum. Different symbols represent the data obtained from individual 542 
experiments. One-way ANOVA and Tukey post-analysis were performed in GraphPad Prism  543 
(version 5.0d). * p < 0.05. (B) Binding of C3 complement protein to S. Typhi strains with 544 
different O-antigen composition. Strains were incubated in human serum followed by anti-C3 545 
FITC-conjugated antibody and surface-bound fluorescence measured with flow cytometry. 546 
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Data is combined from four experiments. MESF = molecules of equivalent soluble 547 
fluorochrome.  One-way ANOVA and Tukey post-analysis were performed in GraphPad 548 
Prism (version 5.0d). * p < 0.05, ** p < 0.01, *** p < 0.001. Error bars indicate mean ± SEM. 549 
 550 
Figure 4. Recognition of S. Typhi O-antigen by serum in a murine immunization model 551 
depends on the O-antigen composition of the immunizing strain. 552 
In a LPS Western blot, LPS from different strains was probed with serum from mice 553 
immunized either with Sty-Basal (A) or STy-FM (B).  In (A), panel #1 (numbered in lower 554 
left hand corner) shows reactivity of pooled serum from the PBS-immunized control group, 555 
and each following panel (2-10) represents the serum from an individual mouse. In (B) panel 556 
#1 shows reactivity of OMA commercial serum, which recognizes several Salmonella 557 
serovars; each following panel represents the serum from an individual mouse.  Lanes 1-4 in 558 
each panel have LPS from the following strains: as follows 1) STy-Basal; 2) STy-Acetyl; 3) 559 
STy-Gluc 4) STy-FM. 560 
 561 
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